Investor Type | Firm |
Industries | BioTech • Pharmaceutical (& Medicine) |
Stages | Seed, Series A |
Investing | United States • United Kingdom |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Assets Under Management | $50,000,000 |
4BIO Capital is a London-based venture investment firm that specializes in the life sciences sector, with a focus on advanced therapies aimed at addressing high unmet medical and social needs. They operate in the Biotech and Pharmaceutical industries and have an expressed interest in areas such as gene therapy, cell therapy, RNA-based therapy, targeted therapies, and the microbiome. With assets under management of 50 million USD, 4BIO Capital supports companies at various stages of growth, notably providing seed and Series A funding. Their investment capacity ranges from a minimum of 100,000 USD to a maximum of 5,000,000 USD, with a sweet spot for investments at around 1,500,000 USD. They aim to generate a real impact by investing in therapeutic advancements that can lead to significant social improvements. As a regulated entity, 4BIO Partners LLP, trading as 4BIO Capital, is authorized and regulated by the Financial Conduct Authority and is also a SEC Registered Investment Advisor. The firm demonstrates a commitment to social impact through their investment practices, seeking out opportunities where the potential for positive community and health outcomes is significant. Their portfolio showcases both current and past investments, indicating an active engagement in the growth and evolution of their selected ventures. The team behind 4BIO Capital is comprised of professionals experienced in life sciences and investment, providing industry knowledge and financial expertise to their portfolio companies.